化疗在晚期非小细胞肺癌治疗中的地位和价值  

The Status and Value of Chemotherapy in Advanced Non-small Cell Lung Cancer

作　　者：陈申[1] 马锐[2] 

机构地区：[1]大连医科大学研究生院,辽宁大连116044 [2]辽宁省肿瘤医院大连医科大学临床肿瘤学院,辽宁沈阳110042

出　　处：《中国肿瘤》2015年第9期737-741,共5页China Cancer

摘　　要：化疗于晚期非小细胞肺癌治疗依然具有举足轻重的作用。以IPASS研究为代表的一系列靶向治疗与化疗头对头对比研究,也证实了化疗依旧是EGFR野生型及突变未明患者一线治疗的首要选择。DELTA研究及CTONG0806研究结果则表明二线治疗中化疗比靶向治疗疗效更优。而LUX-LUNG3/6研究生存数据则表明21外显子突变患者可能更适合于一线化疗。总而言之,化疗是晚期非小细胞肺癌治疗全程管理中不可或缺的。Today,chemotherapy for advanced non-small cell lung cancer is still playing an important role. Represented by IPASS study, a series of RCT research between targeted therapy and chemotherapy confirmed that the chemotherapy remains the first choice for first-line patients with wild type EGFR or uncertain mutation. DELTA and CTONG0806 study results showed that the response with second-line chemotherapy was superior to that with targeted therapy. LUX- LUNG3/6study results showed that patients with 21 exon mutation might be more suitable first-line chemotherapy. To sum up,chemotherapy is indispensable to the whole course of management for advanced non-small cell lung cancer.

关 键 词：非小细胞肺癌 靶向治疗 化疗 

分 类 号：R734.2[医药卫生—肿瘤]